In Tune with the World Trends: Clinical Aspects of Liraglutide Use in Combination with Insulin in Patients with Diabetes Mellitus (Literature Review and Clinical Observations)
There is presented a review of the literature on the treatment of diabetes mellitus type 1 and 2 based on incretin effect, the mechanisms of action, advantages and limitations of a new class of antidiabetic drugs — glucagon-like peptide-1 receptor agonists, their clinical use in combination with insulin, allowing to neutralize the negative effects of the latter. Liraglutide successful clinical use is described in patients suffering from diabetes mellitus type 2 in cases of ineffectively controlled fasting glucose, in the absence of glycemia compensation with high doses of insulin and metformin, as well as in cardiorenal syndrome.
Full Text:PDF (Русский)
Antsiferov MB. Glucagon-like peptide-1: from physiology to the effective management of type 2 diabetes mellitus // Pharmateka. 2012;3:9-15. (Russian)
Коrpachev VV. et al. Guidance on the clinical study of hypoglycemic medicinal facilities for patients with diabetes mellitus. Кyiv: Аvitsena, 2005:96 s. (Ukrainian)
Коrpachev VV. Insulin and insuline therapy. Киyiv: Тriumph, 2001:454 s. (Russian)
Коrpachev VV. Potassium channels and action mechanism of sulphonylureas derivatives. Ukr.Med.Chasopys. 2002;3(29):16-22. (Russian)
Коrpachev VV, Gurina NM. Action mechanisms, safety and bearableness of gliptins – new class of antidiabetic preparations with incretine effects. International Journal of Endocrinology. 2011;7(39):17-22. (Russian)
Коrpachev VV, Gurina NM. Ongliza™ (saxagliptine) - inhibitor of dipeptydilpeptidase-4: incretine effect and clinical application. International Journal of Endocrinology. 2011;1(33):24-36. (Russian)
Коrpachev VV, Pribila ОV, Коrpacheva-Zinych OV, Кushnariova NN, Gurina NM, Коvalchuk АV. Anthropometric, hormonal and biochemical markers of metabolic phenotypes in patients with type 2 diabetes mellitus. Universum: Меdicine and pharmacology. 2016;1-2(24). URL: http://7universum.com/ru/med/archive/item/2945. (Russian)
Pankiv VI. Inretines: new landmark in treatment of type 2 diabetes mellitus. Sitagliptine in the achievement of indemnification of type 2 diabetes mellitus. International Journal of Endocrinology. 2011;6(38):6-12. (Russian).
Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A, Mikhailidis DP. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302-312.
Bose AK, Mocanu MM, Carr RD. et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151.
Buse JB, Bergenstal RM, Glass LC. et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized controlled trial. Ann. Intern. Med. 2011;154:103-112.
Davies MJ, Bain SC, Atkin SL. et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016:39(2):222-230.
Davies MJ, Bain SC, Atkin SL. et al. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Diabetes Care. 2012;35:1446-1454.
Dejgaard-2 TF, Frandsen C, Holst J, Madsbad S. Liraglutide for treating type 1 diabetes. Expert Opin. Biol. Ther. 2016;16(4):579-590.
Dejgaard TF, Frandsen CS, Hansen TS, Almdal T. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221-232.
Drucker D. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 2003;17:161-171.
Drucker D, Philippe J, Mojsov S. et al. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic FMP levels in a rat islet cell line. Proc. Natl. Acad. Sci.USA. 1987;84:3434-3438.
Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocr Metab. 2004;89:3469-3473.
Elbrond B, Jakobsen G, Larsen S. et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398–1404.
Elrick H, Stimmler L, Hlad C, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964;24:1076-1082.
Frandsen CS, Dejgaard TF, Holst J, Andersen H, Thorsteinsson B, Madsbad S. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care. 2010;38(12):2250-2157.
Garber A. Incretin effects on beta-cell function, replication and mass: the human perspective. Diabetes Care. 2011;34(2):258-263.
Inzucchi SE, Bergensta RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
Inzucchi SE, Bergensta RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.
Halland M, Bharucha AE. Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus. Clin. Gastroenterol. Hepatol. 2016;14(7):929-936.
Jadinsky M, Pfutzner A, Paz-Pacheco E. Saxagliptin given in combination with metformin in patients with type 2 diabetes, compared with either monotherapy: a randomised controlled trial. Diabetes Obes. Metab. 2009;10:110-115.
Kahn SE, Haffner SM, Heise MA. et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355:2427-2443.
Kevin M. Pantaloneand Charles Faiman Liraglutide Effective in the Severely Insulin-Resistant Patient with Type 2 Diabetes Requiring U-500 Insulin: A Case Report. Diab. Techn. Ther. 2013;15(4):342-343.
Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011;34(7):1463-1468.
King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. Endocr Pract. 2013;19(1):64-72.
Knudsen LB. et al. Potent derivatives of glucagon-like peptide-1with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 2000;43(9):1664–1669.
Lane W, Weinrib S, Rappaport J, Hale C. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes. Metab. 2014;16(9):827-32.
Lee SJ, Diener K, Kaufman S, Krieger J. et al. Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4. Mol. Metab. 2016;5(7):552-565.
Lee Y, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9-19.
Leech CA, Dzhura I, Chepurny OG, Kang G, Schwede F, Genieser HG, Holz GG. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog. Biophys. Mol. Biol. 2011;7(2):236-247.
Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim. Care Diabetes. 2012;6:41-46.
Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S. et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015;101(1):364.
Mathieu C, Rodbard HW, Cariou B. et al. BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16(7):636-644.
Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2008;17(6):845-853.
Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23-65.
Nathan DM, Buse JB, Davidson MB. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17-30.
Nauck M, Heimesaat M, Orskov C. et al. Preserved incretin activity of glucagon-like peptide-1 [7-36] amide but not not synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993;91:301-307.
Nauck M, Homberger F, Siegel E. et al. Incretin effects of increasing glucose loаds in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986;63:492-498.
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 2013;15(3):204-212.
Nikolaidis LA, Mankad S, Sokos GG. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–5.
Nystrom T, Gutniak MK, Zhang Q. et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am.J. Physiol. Endocrinol Metab. 2004;287:1209–1215.
Pieber TR, Deller S, Korsatko S, Jensen L, Christiansen E, Madsen J, Heller SR. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes. Metab. 2015;17(8):742-750.
Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann. Pharmacother. 2011;45(7-8):850-860.
Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, Heptulla RA. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33(6):1294-1296.
Riedel AA. et al. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am. J. Manag. Care. 2007;13:457-463.
Rodbard HW. et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 2009;15:540-559.
Rosenstock J, Rodbard HW, Bain SC. et al. (Liraglutide-Detemir Study Group). One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J. Diab. Compl. 2013;27:492-500.
Schjoldager B, Mortensen P, Christiansen J. et al. GLP-1 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 1989;34:703-708.
Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide for the treatment of type 2 diabetes. Health Technol. Assess. 2011;15(1):77-86.
Steensgaard DB. et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes. 2008;57(1):552.
Sun F, Chai S, Li L, Yu K, Yang Z, Wu S, Zhang Y, Ji L, Zhan S. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis. J. Diabetes Res. 2015;2015:157201.
Tucker ME. New Era' of Type 2 Diabetes Treatment as LEADER Unveiled? N. Engl. J. Med. 2016. – Published online June 13, 2016.
Tzefos M, Olin J. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus. Ann. Pharmacother. 2010;44:1294-1300.
Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, Chaudhuri A. Liraglutide as additional treatment for type 1 diabetes. Eur. J. Endocrinol. 2011;165(1):77-84.
Vergès B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37(6):477-488.
Vilsboll T. et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–1119.
Vora J, Bain SC, Dzida T. et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab. 2013;39:6–15.
Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci. Rep. 2016;6:18904.
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018